<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00037869</url>
  </required_header>
  <id_info>
    <org_study_id>ID01-063</org_study_id>
    <nct_id>NCT00037869</nct_id>
  </id_info>
  <brief_title>High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors</brief_title>
  <official_title>High Dose I-131 Metaiodobenzylguanidine (MIBG) Therapy for Metastatic Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if I-131 Metaiodobenzylguanidine (MIBG)&#xD;
      can shrink or slow the growth of the tumor(s) in patients with metastatic neuroendocrine&#xD;
      tumors. The safety of this treatment will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MIBG is used to visualize a group of specific cells in the body. It has been known to deliver&#xD;
      the radioactive iodine to the tumor (cancer) cells selectively and result in their&#xD;
      destruction.&#xD;
&#xD;
      Before treatment starts, patients will be evaluated with a tracer scan, using either I-131&#xD;
      MIBG or I-123 MIBG to locate the tumor site(s). If no MIBG accumulation can be found within&#xD;
      tumor sites, the patient will not be able to continue on this study. Patients will also have&#xD;
      CT scans and urine and blood tests. Women able to have children will have a pregnancy test.&#xD;
&#xD;
      If tumor sites are found and patients are fully eligible, they will receive a therapeutic&#xD;
      (treatment) dose of I-131 MIBG by vein over 120 minutes. Some patients may have to receive a&#xD;
      lower dose of MIBG. Patients will require hospitalization for treatment and will remain&#xD;
      hospitalized for about 3-6 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Metastases, Neoplasm</condition>
  <arm_group>
    <arm_group_label>MIBG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose I-131 Metaiodobenzylguanidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>I-131 Metaiodobenzylguanidine</intervention_name>
    <arm_group_label>MIBG</arm_group_label>
    <other_name>MIBG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 2 years of age and older&#xD;
&#xD;
          -  Sex: male or female; female patients with child bearing potential must have a negative&#xD;
             serum HCG pregnancy test within 72 hours prior to treatment;&#xD;
&#xD;
          -  Diagnostic criteria- Patients must meet all of the following:&#xD;
&#xD;
               1. Histologically documented neuroendocrine tumor.&#xD;
&#xD;
               2. Labeled MIBG concentration in the tumor site(s) on diagnostic scan.&#xD;
&#xD;
               3. good to excellent performance status.&#xD;
&#xD;
          -  A patient for whom written voluntary informed consent has been obtained prior to study&#xD;
             and participation.&#xD;
&#xD;
          -  Patients can have had prior chemotherapy, as long as hematological parameters meet&#xD;
             specifications.&#xD;
&#xD;
          -  Please refer to Appendix D Drugs and Other Interactions for list of medications&#xD;
             patient needs to cease 2 weeks prior to therapy. Patient should check with primary&#xD;
             physician after therapy about resuming these medications.&#xD;
&#xD;
          -  Patients with treatment refractory or relapsed advanced or disease not amendable to&#xD;
             significant response (&gt;25% to available chemotherapy) or metastatic disease not&#xD;
             amenable to standard therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with inadequate hematopoietic bone marrow function: ANC&lt;1000 cells/mm3, or&#xD;
             platelets&lt;75k cells/mm3 or hemoglobin&lt;10g/dL.&#xD;
&#xD;
          -  Patients with impaired renal function: creatinine&gt;1.5mg/dL.&#xD;
&#xD;
          -  Patients with impaired hepatic function: AST or ALT &gt; 3.0 X upper limit of normal or&#xD;
             total bilirubin &gt; 2.0 mg/dL.&#xD;
&#xD;
          -  Patients with dementia or altered mental status that would prohibit the giving and&#xD;
             understanding of informed consent at time of study entry.&#xD;
&#xD;
          -  Female patients who are breast-feeding.&#xD;
&#xD;
          -  Children less than 2 years of age.&#xD;
&#xD;
          -  Patients with previous total body irradiation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Podoloff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>May 24, 2002</study_first_submitted>
  <study_first_submitted_qc>May 24, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2002</study_first_posted>
  <last_update_submitted>October 30, 2018</last_update_submitted>
  <last_update_submitted_qc>October 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic neuroendocrine tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

